MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why VCEL Stock surged +4.43% Today — RQD Quant Desk Flash
$42.91 +4.43% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $43.17
Vericel Corporation (VCEL) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C+ • HOLD / WATCH
Cap $2.20B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $43.17 (+0.61%)🧬 Disciplined Float (+1.08% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 9% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C+
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk B+
Each axis scored 0–20
12M PRICE TARGET CONE+4.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCEL)Realized 20D OHLCV Swing Band: ±8.3%
Deterministic 5-Pillar Attribution (67/100 Composite)
🔍 WHY VCEL SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (27% of score)
Altman Z-Score 9.94 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 9% FCF Margin ($24.7M FCF) & 74.4% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution8/20 pts (-12 pt drag)
Disciplined Float (+1.08% YoY Shares) & executive Form 4 sales trim 12 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$40.10+0.1% Next Q
59
Q2 (-2Q)Grade C+$40.13+6% Next Q
62
Q3 (-1Q)Grade C+$42.53+0.9% Next Q
64
CurrentGrade C+$42.91+1.6% Hist 90D α
67
Trajectory: C (59) → C+ (67)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the VCEL Bull Thesis Could Fail
Even with a 67/100 (C+) score, VCEL faces multiple-compression risk if 133.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Priced at 133x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($40.58) or 200D SMA ($38.65) invalidates the momentum regime and cuts Target Base ($44.65) toward Bear Floor ($34.83).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCEL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VCEL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VCEL Stock surged +4.43% Today — RQD Quant Desk Flash
Vericel Corporation (VCEL) surged +4.43% to $42.91, trading at 69% of its 52-week range ($28.95 – $49.32). Solid 74% profit margin (3% return on capital), mixed timing at 133x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 69% of its 52-week range ($28.95 – $49.32) with RSI-14 at 46.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.3% around $42.91 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 74.4% gross margin and $24.7M annual free cash flow.
Live VCEL Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (VCEL Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VCEL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.55%⚡ TESTING RESISTANCE
2026-10-30O $43.02H $43.02L $40.01C $42.91VOL 598.7K
RES: $43.47SUP: $40.08SMA50: $40.58SMA200: $38.65
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VCEL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
48.0%/yr Implied 5Y Growth
vs. +16.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VCEL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VCEL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VCEL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCEL)
Health Care Rank #118 of 1016
⚔️ BCRX vs VCEL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VCEL vs. BCRX, MESO, VIR, ALVO)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vericel Corporation (VCEL) ranks #118 by composite RQD confidence (67/100, grade C+) and #245 by equity capitalization ($2.20B). Within this direct 5-issuer industry benchmark cohort, BCRX leads on earnings valuation at 8.3x trailing P/E, while BCRX leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. BCRX currently holds the highest overall quantitative score in the immediate peer group at 78/100 (B+) compared with VCEL at 67/100 (C+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VCEL
ACTIVE
Vericel Corporation | C+ | 67/100 | 133.0x | 74.4% | 3.4% | +4.43% | $2.20B | Benchmark Subject |
| BCRX BioCryst Pharmaceuticals Inc. | B+ | 78/100 | 8.3x | — | 85.0% | +1.79% | $2.18B | /bcrx-vs-vcel → |
| MESO Mesoblast Limited | C- | 60/100 | — | — | — | +17.03% | $2.04B | /meso-vs-vcel → |
| VIR Vir Biotechnology Inc. | E | 31/100 | — | 96.0% | -35.0% | -1.51% | $2.01B | /vir-vs-vcel → |
| ALVO Alvotech | D+ | 58/100 | — | — | — | -1.01% | $1.91B | /alvo-vs-vcel → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000887359In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vericel Corporation (VCEL) reported GAAP revenue of $276.3M (+16.5% vs. FY2024 revenue of $237.2M , and +39.9% cumulative change since FY2023) , GAAP net income of $16.5M, operating cash flow of $51.9M, and free cash flow of $24.7M (+525.9% YoY). On the balance sheet, VCEL closed FY2025 with $488.0M in total assets against $0 in total debt (Altman Z-Score: 9.94, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $276.3M | $16.5M | $51.9M | $24.7M | $488.0M | — |
| FY2024 (FY) | 2024-12-31 | $237.2M | $10.4M | $58.2M | -$5.8M | $432.7M | — |
| FY2023 (FY) | 2023-12-31 | $197.5M | -$3.2M | $35.3M | $35.3M | — | — |
3. VCEL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VCEL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Vericel Corporation (NASDAQ: VCEL) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $42.91 (+4.43% 1D, market cap $2.20B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 8/20. Across 1016 tracked Health Care issuers, VCEL ranks #118 in composite RQD confidence.
How does VCEL compare to BCRX and MESO in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), VCEL carries a Roarable C+ (67/100 RQD), trailing P/E of 133.0x, gross margin of 74.4%, and ROIC of 3.4%. By comparison, BCRX (BioCryst Pharmaceuticals Inc.) holds a B+ grade (78/100 RQD, P/E 8.3x, ROIC 85.0%, cap $2.18B) and MESO (Mesoblast Limited) posts a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $2.04B). Among the 5-stock peer group, BCRX leads on earnings multiple (8.3x) while BCRX leads on capital efficiency (85.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VCEL?
Per VCEL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000887359), Vericel Corporation generated $276.3M in revenue (+16.5% YoY), $16.5M in net income, and $24.7M in free cash flow against $488.0M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VCEL trading relative to its 50-day, 200-day, and 52-week technical levels?
VCEL last traded at $42.91 (+4.43% on volume of 544,850 shares), positioning the stock +5.74% above its 50-day simple moving average ($40.58) and +11.02% above its 200-day simple moving average ($38.65). Across its 52-week range of $28.95 to $49.32, VCEL sits at the 68.5% percentile with a 14-day RSI of 46.2 (NEUTRAL RANGE) and an implied next-earnings move of ±8.3% ($39.35 to $46.47).
VCEL Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VCEL stock moving today?
Why VCEL Stock surged +4.43% Today — RQD Quant Desk Flash. Solid 74% profit margin (3% return on capital), mixed timing at 133x P/E—hold if owned, no rush to chase.